<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T15:25:42Z</responseDate>
  <request identifier="oai:figshare.com:article/33867874" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33867874</identifier>
        <datestamp>2026-09-16T18:15:45Z</datestamp>
        <setSpec>category_1</setSpec>
        <setSpec>category_4</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_24</setSpec>
        <setSpec>category_873</setSpec>
        <setSpec>portal_63</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>The Scope Concept:
Defined Chemical Space for Identifying
Ligand-Efficient, Tractable Hits Applied to Drug Discovery Targets
Trypanosomal CLK1, 14–3–3/Estrogen Receptor-α,
and SARS-CoV‑2 Mpro</dc:title>
          <dc:creator>Johanna M. Jansen (2396272)</dc:creator>
          <dc:creator>Wilian Cortopassi (24999058)</dc:creator>
          <dc:creator>Daniel Fuller (3429635)</dc:creator>
          <dc:creator>Peter Ertl (329055)</dc:creator>
          <dc:creator>Eric Fang (3909934)</dc:creator>
          <dc:creator>Rishi Raj Gupta (1989082)</dc:creator>
          <dc:creator>Weiping Jia (44939)</dc:creator>
          <dc:creator>Jan Jiricek (619074)</dc:creator>
          <dc:creator>Mark Knapp (1693639)</dc:creator>
          <dc:creator>Andreas Lingel (2360662)</dc:creator>
          <dc:creator>John Manchester (2303572)</dc:creator>
          <dc:creator>Stephanie Moquin (18145682)</dc:creator>
          <dc:creator>Robert Moreau (276840)</dc:creator>
          <dc:creator>Debjani Patra (13280455)</dc:creator>
          <dc:creator>Liliana Pedro (4909141)</dc:creator>
          <dc:creator>Keith Pfister (2160925)</dc:creator>
          <dc:creator>Olivier Rene (24999061)</dc:creator>
          <dc:creator>Patrick Rudewicz (1693648)</dc:creator>
          <dc:creator>Manuel Saldivia (345698)</dc:creator>
          <dc:creator>Ansgar Schuffenhauer (2114851)</dc:creator>
          <dc:creator>Colin Skepper (24999064)</dc:creator>
          <dc:creator>Vanja Stojkovic (24580940)</dc:creator>
          <dc:creator>Jenny Tang (13133347)</dc:creator>
          <dc:creator>Paolo Tosco (1934965)</dc:creator>
          <dc:creator>Tiffany Tsang (3909943)</dc:creator>
          <dc:creator>Sarah Williams (2968740)</dc:creator>
          <dc:creator>Kelly Yan (14560392)</dc:creator>
          <dc:creator>Charles Wartchow (1936987)</dc:creator>
          <dc:subject>Biophysics</dc:subject>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Evolutionary Biology</dc:subject>
          <dc:subject>Chemical Sciences not elsewhere classified</dc:subject>
          <dc:subject>provide meaningful diversity</dc:subject>
          <dc:subject>native mass spectrometry</dc:subject>
          <dc:subject>molecular glue project</dc:subject>
          <dc:subject>fully elaborated molecules</dc:subject>
          <dc:subject>2 main protease</dc:subject>
          <dc:subject>chemical property ranges</dc:subject>
          <dc:subject>based chemical spaces</dc:subject>
          <dc:subject>defined chemical space</dc:subject>
          <dc:subject>cover chemical space</dc:subject>
          <dc:subject>case studies include</dc:subject>
          <dc:subject>tractable hits applied</dc:subject>
          <dc:subject>scope chemical space</dc:subject>
          <dc:subject>considering ligand efficiency</dc:subject>
          <dc:subject>enhancing compound libraries</dc:subject>
          <dc:subject>scope ring systems</dc:subject>
          <dc:subject>efficient hit validation</dc:subject>
          <dc:subject>scope screening set</dc:subject>
          <dc:subject>chemical space</dc:subject>
          <dc:subject>scope principles</dc:subject>
          <dc:subject>studies exemplify</dc:subject>
          <dc:subject>preferred set</dc:subject>
          <dc:subject>ligand efficiency</dc:subject>
          <dc:subject>obtaining hits</dc:subject>
          <dc:subject>efficient hits</dc:subject>
          <dc:subject>compound quality</dc:subject>
          <dc:subject>compound acquisition</dc:subject>
          <dc:subject>scope concept</dc:subject>
          <dc:subject>yield low</dc:subject>
          <dc:subject>sufficient functionality</dc:subject>
          <dc:subject>selected physical</dc:subject>
          <dc:subject>organizing principle</dc:subject>
          <dc:subject>micromolar potency</dc:subject>
          <dc:subject>list triaging</dc:subject>
          <dc:subject>identifying ligand</dc:subject>
          <dc:subject>higher concentrations</dc:subject>
          <dc:subject>finding campaigns</dc:subject>
          <dc:subject>estrogen receptor</dc:subject>
          <dc:subject>demonstrated value</dc:subject>
          <dc:subject>changed practices</dc:subject>
          <dc:subject>biochemical methods</dc:subject>
          <dc:description>Scope is a hit-finding concept that explores a chemical
space in
between fragments and fully elaborated molecules from traditional
low molecular weight (LMW) libraries. It emphasizes high medicinal
chemistry tractability through a focus on compound quality, ligand
efficiency, and selected physical-chemical property ranges. The Scope
chemical space definition seeks to strike a balance between the ability
to cover chemical space with a 10k–50k compound set for medium-throughput
screening and obtaining hits with sufficient functionality to yield
low- to mid-micromolar potency. Scope chemical space is distinct from
other rule-based chemical spaces, and we introduce the concept of
Scope ring systems (ring-X-ring) as both a foundation for intentional
functionalization targeting sufficient potency and as an organizing
principle for characterizing and enhancing compound libraries. A Scope
screening set has been designed from the Scope chemical space for
hit finding with SPR, native mass spectrometry, DSF, and biochemical
methods. This Scope set maintains comparable primary hit rates to
general diversity sets even when screening at higher concentrations,
which allows for efficient hit validation. The Scope set outperforms
diversity sets when considering ligand efficiency and hit rates after
counter-screening, which makes it a preferred set. Case studies include
the trypanosomal CLK1 kinase target, a molecular glue project with
14–3–3 and estrogen receptor-α, and the SARS-CoV-2
main protease. These studies exemplify how the 10k Scope set delivers
diverse and ligand-efficient hits with tractable potency across diverse
binding sites and support the idea that a carefully designed 10k Scope
set can provide meaningful diversity for screening in a broad drug
discovery portfolio. The Scope principles have demonstrated value
in hit-finding campaigns and have changed practices for compound acquisition,
hit-list triaging, and screening.</dc:description>
          <dc:date>2026-09-16T00:00:00Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1021/acs.jcim.6c01654.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/The_Scope_Concept_Defined_Chemical_Space_for_Identifying_Ligand-Efficient_Tractable_Hits_Applied_to_Drug_Discovery_Targets_Trypanosomal_CLK1_14_3_3_Estrogen_Receptor-_and_SARS-CoV_2_Mpro/33867874</dc:relation>
          <dc:rights>CC BY-NC 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
